Starpharma Holdings Limited
(ASX:SPL) says they have secured a licensing agreement for AstraZeneca to use their drug delivery platform.
The deal is part of the development and commercialisation of an AstraZeneca oncology compound with Starpharma in line for a potential earn of up to $300 million in sales milestones and royalties.
The deal also allows for additional products which could double the kickback over the life of the agreement. Starpharma retains the rights outside of the narrow area of application for the product leaving the way open for other licensing deals.
StarPharma made a net loss of $18.95 million for the 2015 financial year.
